| scholarly article | Q13442814 |
| P50 | author | Giampaolo Tortora | Q38544270 |
| Gabriella Fontanini | Q39406171 | ||
| Fortunato Ciardiello | Q43184447 | ||
| Teresa Troiani | Q56953989 | ||
| Bianca Maria Veneziani | Q57174385 | ||
| P2093 | author name string | Vincenzo Damiano | |
| Francesca Carlomagno | |||
| A Raffaele Bianco | |||
| Rosa Caputo | |||
| Roberta Caputo | |||
| Donatella Vitagliano | |||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | endothelium | Q111140 |
| vandetanib | Q7914515 | ||
| P304 | page(s) | 1546-1556 | |
| P577 | publication date | 2003-04-01 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase | |
| P478 | volume | 9 |
| Q40095056 | A new PET tracer specific for vascular endothelial growth factor receptor 2. |
| Q39534408 | A rare case of late-onset lichenoid photodermatitis after vandetanib therapy |
| Q37397228 | Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells |
| Q44324783 | Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13). |
| Q64889753 | An Acquired Epidermal Growth Factor Receptor T790M Mutation after the Addition of Bevacizumab to Preceding Erlotinib Monotherapy in a Lung Cancer Patient with Leptomeningeal Metastases. |
| Q39401628 | Anti-angiogenesis target therapy for advanced osteosarcoma (Review). |
| Q34088265 | Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? |
| Q37347275 | Anti-tumor activity of erlotinib in the BxPC-3 pancreatic cancer cell line |
| Q34854658 | Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancer. |
| Q36909227 | Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma |
| Q36185395 | Antitumor efficacy of colon-specific HPMA copolymer/9-aminocamptothecin conjugates in mice bearing human-colon carcinoma xenografts |
| Q42673264 | Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study |
| Q30557865 | Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck |
| Q36795322 | Combination of radiotherapy with EGFR antagonists for head and neck carcinoma |
| Q37099594 | Combining molecular targeted agents with radiation therapy for malignant gliomas |
| Q36452704 | Current status and perspective of angiogenesis and antivascular therapeutic strategy: non-small cell lung cancer |
| Q37790985 | Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer |
| Q36746141 | DCLAK11, a multi-tyrosine kinase inhibitor, exhibits potent antitumor and antiangiogenic activity in vitro |
| Q38262398 | Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS) |
| Q36129640 | Dual Inhibition of Vascular Endothelial Growth Factor Receptor and Epidermal Growth Factor Receptor is an Effective Chemopreventive Strategy in the Mouse 4-NQO Model of Oral Carcinogenesis |
| Q34928941 | Effectivity of pazopanib treatment in orthotopic models of human testicular germ cell tumors |
| Q40019510 | Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model |
| Q36207730 | Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer |
| Q80103312 | Epidermal growth factor receptor tyrosine kinase inhibitors |
| Q39887931 | Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells. |
| Q47893147 | Evidence-Based Precision Oncology with the Cancer Targetome. |
| Q34471229 | Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas |
| Q33441143 | First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients |
| Q28533949 | From bench to bedside: lessons learned in translating preclinical studies in cancer drug development |
| Q91802338 | Identification of Human Enzymes Oxidizing the Anti-Thyroid-Cancer Drug Vandetanib and Explanation of the High Efficiency of Cytochrome P450 3A4 in its Oxidation |
| Q34314042 | Imaging of VEGF receptor kinase inhibitor-induced antiangiogenic effects in drug-resistant human adenocarcinoma model |
| Q37749564 | Inorganic nanomaterials for tumor angiogenesis imaging. |
| Q36287670 | Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse |
| Q27001295 | Molecular biology of gliomas: present and future challenges |
| Q38128286 | Molecularly targeted drugs for the treatment of cancer: oral complications and pathophysiology |
| Q92344153 | New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma |
| Q36995686 | Novel strategies for treating relapsed/refractory urothelial carcinoma |
| Q64107734 | Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile |
| Q37366243 | PET Imaging of Angiogenesis |
| Q35249646 | PET imaging of early response to the tyrosine kinase inhibitor ZD4190 |
| Q43237082 | Pharmacokinetic Drug Interactions with Vandetanib during Coadministration with Rifampicin or Itraconazole |
| Q47830453 | Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine. |
| Q37170005 | Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma |
| Q42944301 | Pharmacokinetics of Vandetanib in Subjects with Renal or Hepatic Impairment |
| Q35154233 | Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients |
| Q34765380 | Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas |
| Q36677934 | Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers |
| Q39463417 | Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin |
| Q30475818 | Preclinical molecular imaging of tumor angiogenesis. |
| Q37706510 | Preclinical pharmacodynamic evaluation of drug candidate SKLB-178 in the treatment of non-small cell lung cancer |
| Q33868602 | Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects |
| Q47640245 | Rare upper gastrointestinal hemorrhage of cetuximab: A case report |
| Q36883658 | Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors |
| Q36718606 | Second-line Therapy for advanced non-small-cell lung cancer |
| Q37307832 | Small molecule tyrosine kinase inhibitors in pancreatic cancer |
| Q41593429 | Strategies targeting angiogenesis in advanced non-small cell lung cancer |
| Q35622461 | TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis. |
| Q37816164 | Target Inhibition in Antiangiogenic Therapy A Wide Spectrum of Selectivity and Specificity |
| Q35147151 | Targeted Treatment of Differentiated and Medullary Thyroid Cancer |
| Q36616922 | Targeted antitumour therapy--future perspectives |
| Q34217687 | Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model |
| Q37290448 | Targeted therapies in the management of metastatic bladder cancer |
| Q33589345 | Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells. |
| Q40217655 | Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer |
| Q98466261 | Targeting the Extra-Cellular Matrix-Tumor Cell Crosstalk for Anti-Cancer Therapy: Emerging Alternatives to Integrin Inhibitors |
| Q37287554 | The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues |
| Q33514437 | The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma |
| Q33385649 | The marine-derived oligosaccharide sulfate (MdOS), a novel multiple tyrosine kinase inhibitor, combats tumor angiogenesis both in vitro and in vivo |
| Q40526489 | The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model |
| Q37137412 | Therapeutic approaches to target cancer stem cells |
| Q31048848 | Trans-Differentiation of Neural Stem Cells: A Therapeutic Mechanism Against the Radiation Induced Brain Damage |
| Q34160907 | Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion |
| Q38020834 | Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer |
| Q35569079 | Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents |
| Q34147360 | Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. |
| Q38098931 | Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma. |
| Q42097124 | Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism? |
| Q30455612 | Vascular endothelial growth factor as an anti-angiogenic target for cancer therapy |
| Q36611278 | ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoprotein |
| Q33870872 | ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain |
| Q36146888 | ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity |
Search more.